Side effects of dehydroepiandrosterone in gnc, who should not take dehydroepiandrosterone and who should not take H-n, the side effects of long-term use of dehydroepiandrosterone remain to be evaluated. Because in theory, taking DHEA will increase the levels of testosterone and estrogen. Today I will tell you about the side effects of dhea. (The side effects of dehydroepiandrosterone are not suitable for people who eat gnc dehydroepiandrosterone)
First, the side effects of dehydroepiandrosterone
The short-term side effects of dehydroepiandrosterone are as follows:
1, taking DHEA may increase the production of male hormones, so women are prone to signs of masculinity, such as hair loss, deeper voice and acne on their faces.
2. Supplementing too much DHEA will lead to palpitation or excessive secretion of sebaceous glands.
3. Because DHEA can stimulate the secretion of growth hormone, and too much growth hormone will lead to the formation of cancer cells in the human body, too much DHEA in the body may also cause cancer.
4.DHEA will also increase the risk of prostate cancer, breast cancer and uterine cancer, and even make these hormone-sensitive cancer cells more active and worse.
5. After menopause, women usually take hormone therapy to maintain hormone balance in the body. If you take this anti-aging pill, the hormones in your body will increase, which will greatly increase your risk of breast cancer.
6. Excessive use of DHEA by men may also lead to testicular atrophy's disease, male baldness, hypertension or testosterone-related cancer.
However, the mechanism of DHEA in human body has not been clear in scientific research, and the effect of enhancing sexual desire has not been confirmed. Blind long-term excessive supplementation of DHEA may produce some unexpected side effects.
There is no targeted detection of DHEA in clinic, and there is no saying that "DHEA will be supplemented if it is missing". In a word, most doctors don't advocate people taking DHEA health care products themselves, because androgen has a strong function and needs to be supplemented after consulting a professional doctor. Male patients with moderate and severe prostatic hyperplasia, tumor, polycythemia, severe sleep apnea syndrome and liver cancer should not take DHEA to avoid serious complications.
Nesser said: "No one should take DHEA alone without the guidance of a doctor and regular examination of steroid and cholesterol levels and glucose tolerance in the body."
Dr Samuel Yan, a professor of reproductive medicine at the University of California, San Diego, said: "We know very little about DHEA, and the advertisements are blown too hard. I have repeatedly stressed that before the study is clear, if you must win DHEA, you must be cautious. "
Second, who should not eat dhea?
Products containing dehydroepiandrosterone are strictly prohibited in the United States. As mentioned above, we actually know very little about dhea. So it's not that some people shouldn't eat, but that most people don't eat easily. If you really want to take it, please take it under the guidance of a doctor.
Although dhea products are banned in the United States, other countries have also done other research considering the needs of women's endocrine health and recuperation. The American Endocrinology Society, the American College of Obstetrics and Gynecology (ACOG), the American Society of Reproductive Medicine (ASRM), the European Endocrinology Society (ESE) and the International Postmenopausal Society (IMS) jointly appointed a working group to reevaluate the published data on DHEA. The essential difference between DHEA derivatives DHEAAMH, DHEAAMH and DHEA is that DHEAAMH is the product of the scientific team reassembling more than 30 kinds of energy egg sources necessary for raising eggs and nesting, which not only solves the safety problem of DHEA, but also has significant effects on ovaries, immunity and eggs.
1 What is DHEAAMH?
At the beginning of the 20th century, FDA listed DHEAAMH's research achievements as "top secret scientific and technological achievements strictly closed to developing countries". Different from pure DHEA, DHEAAMH has gathered more than 30 kinds of energy factors, which can be used as energy factors for intensive and urgent fertility problems such as raising eggs and nesting, and is regarded as an energy source for assisting pregnancy in Europe. Britain, Germany and many other European countries have done a lot of research on DHEAAMH.
In recent years, the application of dehydroepiandrosterone in patients with ovarian dysfunction has been recognized by many countries. According to the survey, about13 fertility centers around the world began to add DHEAAMH to patients with ovarian dysfunction. When DHEAAMH can't be used, scholars have to use large doses of ovulation-promoting drugs to superovulate. In most cases, the cost is high and the response is low, and the clinical effect is uncertain. It has been recognized that the number of ovulation and pregnancy rate can be increased by using dehydroepiandrosterone.
2 DHEAAMH suitable population
1, women with premature ovarian failure;
2. Women who are pregnant and do IVF;
3. People with disharmony in sexual life;
4. menopausal people;
5. Older women;
6. Hormone levels need to be balanced;
7. Polycystic syndrome;
8. Endometrial repair;
9. Women who improve embryo quality.
Clinical data of 3d ovarian function improvement
Ovarian reserve reduces the number of female aneuploid embryos and embryo transfer. Pretreatment with DHEAAMH for at least about 65438 0 months, preferably at least about 4 months, can increase the number of oocytes and embryos, egg and embryo quality, cumulative pregnancy rate, IVF pregnancy rate and pregnancy time of women.
To evaluate the incidence of aneuploidy in in vitro fertilization embryos. These embryos came from 27 ovulating women who underwent continuous IVF cycles, and these women also received preimplantation genetic diagnosis (PGD). During these cycles, 19 patients received in vitro fertilization without DHEAAMH treatment, and 8 patients received DHEAAMH supplementation at least 4 weeks before in vitro fertilization.
DHEAAMH treatment can increase the number of oocytes (10.4. 7.3 versus 8.5. 4.6) from about 8.5 to about 10.4. Compared with the untreated IVF cycle, DHEAAMH treated IVF cycle (8/8, 100%) has at least one diploid embryo available for transplantation (10/ 19, 52.6%; Likelihood ratio, p = 0.004 Fisher exact test, p= 0.026). However, in this case, there is no significant difference in the absolute number and percentage of aneuploid embryos after DHEAAMH, but there is no significant difference between untreated and treated patients.
With the increase of women's age, the rate of embryo aneuploidy will drop sharply. Therefore, the increase of aneuploidy results in elderly women is an important evidence of the effectiveness of DHEAAMH in improving embryo quality. Pretreatment with dehydroepiandrosterone for women with ovum failure can significantly increase their chances of transplanting at least one aneuploid embryo.
4 DHEAAMH patent certification
EDQM, EFSA, DNV)ISO900 1+0, HACCP quality system, French and European quality certification, and multinational and multi-agency certification. The patents issued by DHEAAMH R&D are as follows:
Product composition patent FX 4R]
Jean Pierre Rousselot Saskatchewan People's Court #
Jean Pierre Rousselot French SAS, collagen peptide powder HSR t
The quality system certificate of ISO 9001issued by DNV and HACCP issued by DNV.
DQM certificate issued by European Director of Drug Quality (EDQM) and EDQM certificate issued by European Drug Quality Administration (EDQM),
European food import registration (in line with European Council resolution 200 1/556/EC) OE л l (te9 EU food
200 1/556/ECIXR) Unitika co., ltd, ceramide 84 Unitika (er) group ceramide patented new energy product Celamid? FN？ European invention patent? P07 1 49 10B 1
1jep0714910b1U.S. patent 5,846,939 F4FJ 5,846,939 Japanese patent 8.268903 8.44n8.4088888886
Ingredia-lactium casein hydrolysate peptide # Lngredia-actium 7kjt4at actium is one of the few food raw materials that have passed the hygiene certification of French Safety Control Supervision Bureau, and actium is one of the few food raw materials that have passed the hygiene certification of French Safety Control Supervision Bureau.
L actium e нр m/саа (European Food Safety Agency (EFSA) health certification) L actium eh р m/ciaa (EFSAENT 945rab) (EFSA European Food Safety Agency health certification).
Lacium has passed the health certification approved by appprov 1 eerj, the authoritative organization of latiumii 7 # 4 in Korea.
The product patent passed the certification of XFJSEIG EP 07/KOOC-0/49/KOOC-0/0b/KOOC-0/month 30th.
(DGCCRF): The French government of security and control is authorized.
(DGCCRF) (DGCCRF):TQ？ French $ TERM TJ iefettr (DGCC CRF) safety award
oligosaccharide
Invention patent: jp 2001048789acn1283413a.
Oligosaccharide 3T
URJ:jp 200 1048789 a cn 12834 13A
Sausslife's patented manufacturing process
Culture (invention patent: 20051015902.0) T 32' NEI (RJ: 20051015902.0)
Patent no: ZL 20 16 10309204.2 preparation of collagen peptide ine: ZL 201610309204.2hfr? t#Tit
Patent number: ZL 201610318583.1preparation of chitosan oligosaccharide UNIS: ZL 201610318583./kloc.
PatentNo.: ZL 20 16 10345868.4 Preparation of Fructooligosaccharides PatentNo.: ZL 20 16 10345868.4 Preparation of Fructooligosaccharides.
PatentNo.: ZL 201610309219.9 Preparation of Casein Hydrolyzed Peptide
Patent no: ZL 201610309219.9 preparation method of casein hydrolyzed peptide.
PatentNo.: ZL 20181kloc-0/0202737 skin intensive repair elastin and its preparation method.
PatentNo.: ZL 20181kloc-0/0202737 elastic egg white for skin strengthening and repairing and its preparation method.
Korea amicogen Co., Ltd. Collagen Tripeptide Korea Aimeike Bond Co., Ltd. Collagen Tripeptide ApplicationNo.:10-20158019 Patent ApplicationNo.: 10-20 14.
Application number:10-2016-0014896 Patent application number:10-2016-0014896.
Hayashikane Sangyo Co., Ltd., Japanese patent authorization No.5459825 No.5459825 for bonito elastin peptide.
Japanese patent license number 5590704 Japanese patent license number 5590704